Chair and Interim CEO
Dr. Roch Doliveux was appointed to Oxford Biomedica’s Board as Non-Executive Chair in June 2020. Dr. Doliveux also became Interim CEO in January 2022. He is currently Chair of the Board of Directors at Pierre Fabre S.A..Dr. Doliveux was previously the Chief Executive Officer of UCB S.A. for ten years during which time he transformed the company from a diversified chemical group into a global biopharmaceutical leader. Prior to this Dr. Doliveux worked at Schering-Plough International, Inc. from 1990–2003 and at Ciba-Geigy AG (now Novartis) from 1982-1990. Dr. Doliveux is a Veterinary Surgeon by training and has an MBA from INSEAD.
– Nomination committee (Chair)
– Remuneration committee (Dr. Doliveux will not be a member of the Remuneration Committee whilst he serves as interim CEO)